OBJECTIVE: To determine the efficacy and safety of oral dihydroartemisinin-piperaquine (DP, Artekin) in the treatment of uncomplicated Plasmodium falciparum malaria in southern Laos. METHODS: An open, randomized clinical trial of oral artesunate-mefloquine (AM) vs. DP in 220 patients with acute uncomplicated falciparum malaria in Savannakhet Province, Laos. RESULTS: The 42-day cure rates (95% CI), as determined by survival analysis and adjusted for reinfection, were excellent and similar for the two groups [99 (94-100)% and 100 (100-100)% for AM and DP, respectively]. The median (range) fever and parasiteclearance times for the AM and DP groups were also similar [20 (4-63) h and 2 (1-4) days vs. 20 (7-57) and 2 (1-4) days, logrank P = 0.4 and 0.17, respectively]. There were more patients with at least one potential side effect following treatment in the AM group when compared with the DP group [64/110 (58%) vs. 48/110 (44%), respectively, P = 0.031]. CONCLUSION: Dihydroartemisinin-piperaquine did not have superior efficacy to AM for the treatment of uncomplicated falciparum malaria in Laos but was associated with fewer adverse effects.
RCT Entities:
OBJECTIVE: To determine the efficacy and safety of oral dihydroartemisinin-piperaquine (DP, Artekin) in the treatment of uncomplicated Plasmodium falciparum malaria in southern Laos. METHODS: An open, randomized clinical trial of oral artesunate-mefloquine (AM) vs. DP in 220 patients with acute uncomplicated falciparum malaria in Savannakhet Province, Laos. RESULTS: The 42-day cure rates (95% CI), as determined by survival analysis and adjusted for reinfection, were excellent and similar for the two groups [99 (94-100)% and 100 (100-100)% for AM and DP, respectively]. The median (range) fever and parasite clearance times for the AM and DP groups were also similar [20 (4-63) h and 2 (1-4) days vs. 20 (7-57) and 2 (1-4) days, logrank P = 0.4 and 0.17, respectively]. There were more patients with at least one potential side effect following treatment in the AM group when compared with the DP group [64/110 (58%) vs. 48/110 (44%), respectively, P = 0.031]. CONCLUSION:Dihydroartemisinin-piperaquine did not have superior efficacy to AM for the treatment of uncomplicated falciparum malaria in Laos but was associated with fewer adverse effects.
Authors: Richard T Eastman; Neekesh V Dharia; Elizabeth A Winzeler; David A Fidock Journal: Antimicrob Agents Chemother Date: 2011-05-16 Impact factor: 5.191
Authors: Brioni R Moore; Kenneth F Ilett; Madhu Page-Sharp; Jeffrey D Jago; Kevin T Batty Journal: Antimicrob Agents Chemother Date: 2009-04-20 Impact factor: 5.191
Authors: Harin A Karunajeewa; Kenneth F Ilett; Ivo Mueller; Peter Siba; Irwin Law; Madhu Page-Sharp; Enmoore Lin; Jovitha Lammey; Kevin T Batty; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2007-10-29 Impact factor: 5.191
Authors: A R Hasugian; H L E Purba; E Kenangalem; R M Wuwung; E P Ebsworth; R Maristela; P M P Penttinen; F Laihad; N M Anstey; E Tjitra; R N Price Journal: Clin Infect Dis Date: 2007-03-05 Impact factor: 9.079
Authors: Shereen Katrak; Anne Gasasira; Emmanuel Arinaitwe; Abel Kakuru; Humphrey Wanzira; Victor Bigira; Taylor G Sandison; Jaco Homsy; Jordan W Tappero; Moses R Kamya; Grant Dorsey Journal: Malar J Date: 2009-11-30 Impact factor: 2.979
Authors: Julien Zwang; Elizabeth A Ashley; Corine Karema; Umberto D'Alessandro; Frank Smithuis; Grant Dorsey; Bart Janssens; Mayfong Mayxay; Paul Newton; Pratap Singhasivanon; Kasia Stepniewska; Nicholas J White; François Nosten Journal: PLoS One Date: 2009-07-29 Impact factor: 3.240